Vanessa Villard, CEO and co-founder manages all operational and financial aspects of Amylgen. Watch Vanessa’s video at the “prix national du jeune entrepreneur”. She received her PhD in Neurosciences from the University of Montpellier 2. The topic of thesis was « the determination of the antiamnesic and neuroprotective effect of Anavex compounds in a non transgenic model of Alzheimer’s disease ». See Vanessa’s publications
In parallel to running her company, she is studying for an Executive MBA at Sup de Co Montpellier Business School. Finally, yesterday Vanessa received the award 'sciences and technologies''
Amylgen is a privately owned contract research organization (CRO) offering a unique combination of validated in vivo models and a full range of behavioral, biochemical and morphological testing allowing fast and predictive screening of the effects of drugs and nutraceuticals on brain health.
Amylgen is at your service to provide quick POC for your product as a food supplement for brain health and helps you to substantiate the efficacy of your product by preclinical studies in rodent models. Amylgen brings you preclinical scientific data for your product on:
- Brain aging preservation
- Memory enhancement
- Antidepressant /anti anxiety effect
- Protection against Alzheimer’s disease
Amylgen has access to regulatory and clinical partners to aid in the preparation of health claims for EFSA or FDA and the commercialization of your product.
Visit them on the web at amylgen.fr